



G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

July 25, 2024 at 11:15 AM EDT

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: [GTHX](#)), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter of 2024 on Thursday August 8, 2024, at 8:30 a.m. ET.

To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this [link to register online](#). While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the [Events & Presentations](#) page of the company's website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA® (trilaciclib). G1's goal is to provide innovative therapeutic advances for people living with cancer. G1 is based in Research Triangle Park, N.C. For additional information, please visit <http://www.g1therapeutics.com> and follow us on X (formerly known as Twitter) [@G1Therapeutics](#) and [LinkedIn](#).

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contact:

Will Roberts
Communications Officer
Vice President, Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com



Source: G1 Therapeutics